Ado-trastuzumab emtansine (T-DM1): A novel antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer

Journal of Oncology Pharmacy Practice

Volumn 21, Issue 2, 2014, Pages 132-142

  Baron, Jessica M ^a   Boster, Bonnie L ^a   Barnett, Chad M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Ado trastuzumab emtansine; human epidermal growth factor receptor 2 positive; metastatic breast cancer; T DM1

Indexed keywords

ATAZANAVIR; BILIRUBIN; CAPECITABINE; CLARITHROMYCIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; INDINAVIR; ITRACONAZOLE; KETOCONAZOLE; LAPATINIB; NEFAZODONE; NELFINAVIR; RITONAVIR PLUS SAQUINAVIR; TELITHROMYCIN; TRASTUZUMAB EMTANSINE; VORICONAZOLE; ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; ERBB2 PROTEIN, HUMAN; MAYTANSINE; MONOCLONAL ANTIBODY; TUBULIN MODULATOR;

ALOPECIA; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; BLURRED VISION; BREAST METASTASIS; CARDIOTOXICITY; CONJUNCTIVITIS; DIARRHEA; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG FEVER; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRY EYE; EPISTAXIS; ERYTHEMA; EYE DISEASE; FATIGUE; GASTROINTESTINAL HEMORRHAGE; HUMAN; HYPOKALEMIA; INFUSION RELATED REACTION; INJECTION SITE REACTION; INJECTION SITE SWELLING; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RECTUM HEMORRHAGE; SKIN IRRITATION; THROMBOCYTOPENIA; VISUAL IMPAIRMENT; VOLUME OF DISTRIBUTION; VOMITING; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; DRUG EFFECTS; ENZYMOLOGY; FEMALE; METABOLISM; METASTASIS; PATHOLOGY; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOCONJUGATES; MAYTANSINE; NEOPLASM METASTASIS; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TUBULIN MODULATORS;

EID: 84924984158     PISSN: 10781552     EISSN: 1477092X     Source Type: Journal    
DOI: 10.1177/1078155214527144     Document Type: Article

References (31)

1. US Cancer Statistics Working Group. United States Cancer Statistics: 1999-2010 Incidence and mortality web-based report, http://www.cdc.gov/cancer/breast/statistics/ (2013, accessed 15 October 2013).
2. Surveillance, epidemiology, and end results program, http://seer.cancer.gov/statfacts/html/breast.html (2013, accessed 15 October 2013).
3. College of American Pathologists. ASCO-CAP HER2 test guideline recommendations: summary of guideline 2007 and 2013 recommendations, www.cap.org (2013, accessed 1 November 2013).
4. National Comprehensive Cancer Network. Breast Cancer (Version 3.2013), http://www.nccn.org/professionals/physician-gls/f-guidelines.asp#breast (2013, accessed 15 October 2013).
5. Spector NL, Blackwell KL. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2009 ; 27: 5838-5847
6. Genentech. Perjeta (package insert). South San Francisco, CA: Genentech, 2013.
7. Agus DB, Gordon MS, Taylor C, et al. Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J Clin Oncol. 2005 ; 23: 2534-2543
8. GlaxoSmithKline. Tykerb (package insert). Research Triangle Park, NC: GlaxoSmithKline, 2013.
9. Nahta REF. Trastuzumab: triumphs and tribulations. Oncogene. 2007 ; 26: 3637-3643
10. LoRusso PM, Weiss D, Guardino E, et al. Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer. Clin Cancer Res. 2011 ; 17: 6437-6447
11. Chudasama VL, Schaedeli Stark F, Harrold JM, et al. Semi-mechanistic population pharmacokinetic model of multivalent trastuzumab emtansine in patients with metastatic breast cancer. Clin Pharmacol Therapeut. 2012 ; 92: 520-527
12. Genentech. Kadcyla (package insert). South San Francisco, CA: Genentech, 2013.
13. Widdison WC, Wilhelm SD, Cavanagh EE, et al. Semisynthetic Maytansine analogues for the targeted treatment of cancer. J Med Chem. 2006 ; 49: 4392-4408
14. Feld J, Barta SK, Schinke C, et al. Linked-in: design and efficacy of antibody drug conjugates in oncology. Oncotarget. 2013 ; 4: 397-412
15. Lewis Phillips GD, Li G, Dugger DL, et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res. 2008 ; 68: 9280-9290
16. Girish S, Gupta M, Wang B, et al. Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer. Cancer Chemother Pharmacol. 2012 ; 69: 1229-1240
17. Genentech. Herceptin (package insert). South San Francisco, CA: Genentech, Inc., 2010.
18. Krop IE, Beeram M, Modi S, et al. Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J Clin Oncol. 2010 ; 28: 2698-2704
19. Gupta M, Lorusso PM, Wang B, et al. Clinical implications of pathophysiological and demographic covariates on the population pharmacokinetics of trastuzumab emtansine, a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer. J Clin Pharmacol. 2012 ; 52: 691-703
20. Beeram M, Krop IE, Burris HA, et al. A phase 1 study of weekly dosing of trastuzumab emtansine (T-DM1) in patients with advanced human epidermal growth factor 2-positive breast cancer. Cancer. 2012 ; 118: 5733-5740
21. Bender BC, Schaedeli-Stark F, Koch R, et al. A population pharmacokinetic/pharmacodynamic model of thrombocytopenia characterizing the effect of trastuzumab emtansine (T-DM1) on platelet counts in patients with HER2-positive metastatic breast cancer. Cancer Chemother Pharmacol. 2012 ; 70: 591-601
22. Lu D, Modi S, Elias A, et al. Pharmacokinetics of trastuzumab emtansine and paclitaxel or docetaxel in patients with HER2-positive metastatic breast cancer previously treated with a trastuzumab-containing regimen. Poster session presented at: 34rd Annual San Antonio breast cancer symposium (SABCS), San Antonio, TX, USA, 6 - 10 December 2011.
23. Wong S, Bumbaca D, Yue Q, et al. Abstract A136: Nonclinical disposition, metabolism, and in vitro drug-drug interaction assessment of DM1, a component of trastuzumab emtansine (T-DM1). In: AACR-NCI-EORTC International conference: Molecular targets and cancer therapeutics, San Francisco, CA, USA, 12 - 16 November 2011; Mol Cancer Ther 2011; 10(Suppl 1).
24. Demeule B, Palais C, Machaidze G, et al. New methods allowing the detection of protein aggregates: A case study on trastuzumab. MAbs. 2009 ; 1: 9-9
25. Kadcyla. RED BOOK Online. Micromedex Healthcare Series. Greenwood Village, CO: Truven Health Analytics, Inc. Available from: http://www.micromedexsolutions.com/micromedex2/librarian/ (accessed November 2013).
26. Burris HA, Rugo HS, Vukelja SJ, et al. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol. 2011 ; 29: 398-405
27. Krop IE, LoRusso P, Miller KD, et al. A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine. J Clin Oncol. 2012 ; 30: 3234-3241
28. Hurvitz SA, Dirix L, Kocsis J, et al. Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol. 2013 ; 31: 1157-1163
29. Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. New Engl J Med. 2012 ; 367: 1783-1791
30. Dieras V, Harbeck N, Albain K, et al. A phase Ib/II trial of trastuzumab-DM1 (T-DM1) with pertuzumab for patients with HER2-positive, locally advanced or metastatic breast cancer: interim efficacy and safety results. Poster session presented at: 33rd Annual San Antonio breast cancer symposium (SABCS), San Antonio, TX, USA, 8 - 12 December 2010.
31. Thon JN, Devine MT, Jurak Begonja A, et al. High-content live-cell imaging assay used to establish mechanism of trastuzumab emtansine (T-DM1)-mediated inhibition of platelet production. Blood. 2012 ; 120: 1975-1984